Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability and Bioequivalence of Ezetimibe Tablets in Healthy Subjects
NCT05681247Phase 1Completed
- Sponsor
- The Affiliated Hospital of Qingdao University
- Start
- Dec 2017
- Primary completion
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial of ezetimibe in hyperlipidemia (2 arms), sponsored by The Affiliated Hospital of Qingdao University. Primary endpoint: Peak Plasma Concentration at 80 days. Started Dec 2017; status: completed.
02
Drugs
ezetimibe
03
Conditions
hyperlipidemia
Beyond the preview
Go deeper on NCT05681247.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05681247.